The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2016Targeting the Lysosomal Pathway to Ease Mitochondrial Dysfunction in IPSC-Derived Neurons from People with Parkinson's and GBA Mutations
Study Rationale:
Mutations of the GBA gene, which encodes the enzyme glucocerebrosidase (GCase), are associated with Parkinson's, and we have recently shown that loss of GCase activity gives rise to... -
Research Grant, 2016Role of the JAK/STAT Pathway in Parkinson's Disease
Promising Outcomes of Original Grant:
We aim to determine if hyperactivation of the JAK/STAT (cellular signaling) pathway is involved in Parkinson's disease pathology. Using a pre-clinical model of PD... -
Target Advancement Program, 2016Upregulation of Autophagy by Tet3-mediated 5-methylcytosine oxidation – Relevance to Parkinson's Disease
Study Rationale:
An abnormally folded version of the protein alpha-synuclein forms characteristic clumps (Lewy bodies) in nerve cells in Parkinson's disease (PD). One possible reason for this is an... -
Target Advancement Program, 2016Role of PINK1 and Parkin in Innate Immunity: Crosstalk between Mitochondrial Dysfunction and NLRP3 Inflammasome Signaling
Study Rationale:
Mitochondrial dysfunction and neuroinflammation play major roles in Parkinson's disease (PD). Overactivation of the inflammasome (innate immune system receptor) signaling complex NLRP3... -
Target Advancement Program, 2016Evaluation of PARIS (ZNF746) as a Target of Alpha-synuclein Toxicity in Parkinson's Disease and Alpha-synucleinopathies
Study Rationale:
We have recently identified Parkin-Interacting Substrate (PARIS), a Kruppel associated box (KRAB) and zinc finger protein, as a substrate of the parkin, E3 ubiquitin ligase. PARIS... -
Target Advancement Program, 2016Targeting Novel Transcriptional Pathways to Reduce Alpha-synuclein Expression
Study Rationale:
Many scientific studies have shown that one of the major causes of Parkinson's disease (PD) is the accumulation of a protein named alpha-synuclein in a certain type of neurons. When...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.